Best-Practice Ketamine Protocols for Depression: Regulatory and Clinical Guidance (2026)

Short-Term Ketamine in Depression: Current Evidence and Regulatory Status

Short-term ketamine interventions for depressive disorders are increasingly used, but only intranasal esketamine and intravenous (IV) racemic ketamine currently have robust regulatory and clinical trial support. According to the 2026 review published via OpenAlex (source), psychiatrists are turning to a variety of ketamine formulations—oral, subcutaneous, and nasal—for patients with treatment-resistant depression, particularly when rapid symptom reduction is clinically necessary. However, the regulatory landscape remains fragmented: intranasal esketamine (marketed as Spravato) is approved in the United States, European Union, and several other jurisdictions for treatment-resistant depression, while IV racemic ketamine is frequently used off-label based on randomized controlled trial (RCT) evidence but lacks formal psychiatric labeling. Other routes, such as subcutaneous racemic ketamine, oral ketamine, and compounded racemic intranasal sprays, are used off-label and present unique challenges for clinicians and regulators alike.

Mechanisms, Formulations, and Clinical Protocols

Ketamine and esketamine act primarily as N-methyl-D-aspartate (NMDA) receptor antagonists, producing rapid—though often transient—antidepressant effects. The 2026 review synthesizes data from PubMed/MEDLINE, regulatory documents, and clinical guidelines, prioritizing evidence by study design and jurisdictional labeling. Among non-IV options, subcutaneous racemic ketamine emerges as the best-supported off-label approach, with randomized trial evidence supporting flexible, response-guided titration for short-term use. Oral ketamine, including both solution and newer prolonged-release tablet formulations, has limited but promising small-trial and systematic-review support; however, these remain investigational and formulation-specific. Compounded racemic intranasal ketamine shows weaker and more heterogeneous evidence, with variable dosing and absorption profiles.

Protocols for all ketamine interventions should be measurement-based, supervised, time-limited, and embedded within a broader treatment plan. For labeled intranasal esketamine, clinicians are advised to adhere strictly to the product label and Risk Evaluation and Mitigation Strategy (REMS) requirements in the United States (FDA label). For off-label racemic ketamine, particularly subcutaneous administration, the review recommends supervised dosing with objective monitoring and response-guided titration. Oral ketamine may be considered when parenteral or regulated nasal options are inaccessible, but requires heightened caution: controlled dispensing, careful patient selection, and regular monitoring for efficacy and adverse events are essential. Compounded racemic nasal sprays should be reserved for exceptional cases due to inconsistent evidence and regulatory scrutiny.

Policy, Insurance, and Research Implications

The review's recommendations may influence clinical protocols, insurance coverage, and regulatory oversight as off-label ketamine use expands in psychiatric practice. In the United States, insurers typically cover only FDA-approved intranasal esketamine, while IV and subcutaneous racemic ketamine are generally paid for out-of-pocket or via specialty clinics. The increasing use of subcutaneous and oral ketamine—especially in areas where IV access is limited—may prompt payers and regulators to revisit coverage criteria and safety monitoring requirements. Notably, the review highlights that the lack of standardized dosing, frequency, and maintenance strategies for off-label ketamine formulations complicates both clinical decision-making and reimbursement.

From a research perspective, the review identifies a critical need for larger, longer-term RCTs of non-IV ketamine formulations, including head-to-head comparisons with labeled esketamine. The heterogeneity of compounded nasal sprays, in particular, underscores the importance of formulation-specific studies and regulatory clarity. An underappreciated insight is the potential for local pharmacy compounding practices to introduce variability in dosing and absorption, raising both clinical and legal risks that are rarely discussed in mainstream guidance.

Risks, Unknowns, and Failure Modes

All ketamine interventions carry risks, including dissociation, blood pressure elevation, substance use liability, and potential for misuse or diversion. For off-label racemic ketamine—especially oral and compounded nasal forms—optimal dosing, frequency, durability of response, long-term safety, and maintenance strategies remain incompletely established. The review cautions that oral ketamine's variable bioavailability and slower onset may increase the risk of subtherapeutic dosing, while compounded nasal sprays can result in unpredictable absorption and effect profiles. Additionally, the absence of standardized monitoring protocols increases the risk of missed adverse events and complicates post-market surveillance.

A real-world failure mode, not widely acknowledged in competitor analyses, is the risk of "protocol drift" in community clinics: as off-label use proliferates, some providers may deviate from evidence-based regimens, increasing both clinical risk and legal exposure. The review underscores the importance of protocolized, measurement-based care, with regular reassessment and clear discontinuation criteria to mitigate these risks.

Looking Ahead: Regulatory and Clinical Developments

The trajectory of ketamine-based interventions in depression will depend on forthcoming trial results, evolving regulatory frameworks, and payer policies. As of mid-2026, subcutaneous racemic ketamine stands out as the best-supported non-IV, off-label option for short-term intervention, but its long-term safety and comparative efficacy remain to be established. The review anticipates that insurance coverage, regulatory scrutiny, and clinical uptake will increasingly hinge on the availability of robust, formulation-specific evidence and standardized protocols. For clinicians, the key is to balance rapid symptom relief with careful patient selection, objective monitoring, and adherence to evolving best practices. For researchers and policymakers, the imperative is to close evidence gaps and ensure that expanding access to ketamine is matched by rigorous safety and efficacy oversight.

By Dr. Alex M. Carter, MD, MSc, Clinical Psychiatrist and Research Fellow. Reviewed by Dr. Jamie Lee, PharmD, on 2026-09-04. Research based on primary regulatory, clinical trial, and peer-reviewed sources.